<DOC>
	<DOCNO>NCT00364611</DOCNO>
	<brief_summary>Pilot , phase II , parallel-group , open-label , noncomparative , prospective , multicenter study design evaluate progression-free survival docetaxel bevacizumab Â± trastuzumab first-line treatment participant metastatic breast cancer . Participants stratify accord human epidermal growth factor receptor-2 ( HER2 ) status time enrollment . HER2 negative participant assign receive docetaxel bevacizumab ( DB ) . HER2 positive participant assign receive docetaxel , bevacizumab , trastuzumab ( DBT ) . All participant ( except one ) study treatment 30 June 2011 . All efficacy analysis safety analysis perform use cut-off date June 2011 . One participant continue treatment till 11 March 2012 . For participant , adverse event collect upto 19 April 2012 include safety analysis .</brief_summary>
	<brief_title>Pilot Study Docetaxel &amp; Bevacizumab +/- Trastuzumab First-Line Treatment Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>The study include : - Study registration Day 1 : Treatment Cycle 1 initiate within 14 day sign informed consent - Treatment administer 3 week treatment cycle participant develop unacceptable toxicity , disease progression , withdraw consent , die - If participant experience complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) Cycle 8 beyond unacceptable toxicity due docetaxel , could continue bevacizumab and/or trastuzumab develop unacceptable toxicity , disease progression , withdraw consent - Participants follow-up assessment within 30 day discontinuation treatment last study drug reason death</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow participant physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . INCLUSION CRITERIA : 1 . Histologically cytologically proven adenocarcinoma breast first diagnosis 2 . Stage IV disease least one measurable lesion accord RECIST criterion 3 . HER2/neu positive determine 3+ immunohistochemistry ( IHC ) stain fluorescence situ hybridization ( FISH ) positivity negative tumor 4 . Life expectancy &gt; /= 24 week 5 . No prior chemotherapy metastatic breast cancer . ( Prior endocrine therapy permit ) . 6 . Prior neoadjuvant adjuvant chemotherapy permit , least 12 month must elapse since neoadjuvant adjuvant therapy . Subjects may receive prior adjuvant anthracyclines ( maximum cumulative dose , 360 mg/m^2 doxorubicin 750 mg/m^2 epirubicin ) 7 . At least 4 week since prior surgery , radiotherapy , endocrine therapy , experimental drug therapy complete recovery effect intervention 8 . It recommend baseline staging complete within 35 day prior study entry . All subject follow workup applicable ; CT scan brain , CT scan MRI chest abdomen , bone scan PET scan . In case positive bone PET scan , bone Xray evaluation and/or MRI require confirm exclude metastatic bone disease . Subjects metastatic disease limit bone ineligible unless least one lytic lesion measurable follow RECIST criterion . Other test may perform clinically indicated 9 . Normal cardiac function must confirm leave ventricular ejection fraction ( LVEF ) &gt; /= 50 % shorten fraction ( multiplegated acquisition [ MUGA ] scan echocardiography respectively ) . The result must great low limit normal ( LLN ) institution . 10 . Subjects receive bisphosphonate therapy ; however , bisphosphonates start within &lt; 2 month prior treatment bone lesion evaluate response , subject must another site metastatic disease either measurable evaluable response EXCLUSION CRITERIA : 1 . Prior chemotherapy metastatic breast cancer 2 . Prior treatment bevacizumab antiVEGF therapy 3 . Concurrent treatment nonprotocol anticancer therapy exception radiation therapy long target lesion follow radiation field HER2/neu positive , HER2/neudirected therapy 4 . Current prior history brain leptomeningeal metastases 5 . Presence neuropathy &gt; /= 2 6 . Presence nonhealing wound , fracture , ulcer , presence clinically significant ( &gt; /= Grade 2 ) peripheral vascular disease 7 . History malignancy within past 5 year , exception nonmelanoma skin cancer carcinoma insitu cervix 8 . Clinically significant cardiovascular disease 9 . Active peptic ulcer disease , inflammatory bowel disease , gastrointestinal condition increase risk perforation ; history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior begin therapy 10 . History bleed diathesis coagulopathy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>